secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scholar Rock Holding Corp (SRRK)
CIK:        0001727196
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001558370-24-006906
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scholar Rock Q1 net loss $56.9M ($0.59/shr); Phase 3 SMA data on track for Q4 2024
--------------------------------------------------------------------------------

- Net loss $56.9M ($0.59/shr) vs $39.4M ($0.49) Q1 2023; no revenue; R&D up 45% to $43.1M.
- Cash $238M as of March 31, 2024; expected to fund operations into 2H 2025.
- Phase 3 SAPPHIRE top-line data for apitegromab in SMA on track for Q4 2024; potential commercial launch in 2025 if successful.
- Initiating Phase 2 proof-of-concept trial of apitegromab + GLP-1 RA in obesity in June 2024; data expected mid-2025.
- SRK-181 data selected for oral presentation at ASCO 2024; SRK-439 preclinical data at ADA 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1727196/000155837024006906/0001558370-24-006906-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1727196/000155837024006906/srrk-20240507x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-006906

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer